Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
New Horizon Health Ltd.
Headquarters: Hangzhou, China
Website: http://www.newhorizonbio.co...
Year Founded: 2015
Status: Public
Industry Sector: HealthServices
CEO: Ye Qing Zhu, MBA
Number Of Employees: N/A
Enterprise Value: N/A
PE Ratio: 53.81
Exchange/Ticker 1: HKEX:6606
Exchange/Ticker 2: N/A
Latest Market Cap: $812,389,133
BioCentury | Aug 20, 2021
Finance
Privacy law sparks China biotech’s latest sell-off
Loncar China ETF sees half its companies fall at least 5%
BioCentury | Jul 21, 2021
Finance
Qiming looks to tap China’s public biotech boom
With Fidelity veteran Jane Wu as CIO, firm launches $500M hedge fund to invest in public equities
BioCentury | Feb 19, 2021
Finance
Feb. 19 Quick Takes: New Horizon triples in Hong Kong IPO; plus Alta, Hangzhou Sciwind, Molecular Templates, BeiGene-BITT and Charles River-Cognate
New Horizon Health Ltd (HKEX:6606) climbed HK$57.34 (215%) to HK$84 in its first day of trading this week after becoming the first diagnostics company to list on the Hong Kong stock
BioCentury | Feb 13, 2021
Finance
Qiming readies to kick off Chinese New Year with a first for Hong Kong exchange
Portfolio company New Horizon readies to become first diagnostics play on the Hong Kong exchange’s biotech chapter
BioCentury | Nov 19, 2020
Finance
Nov. 18 Quick Takes: Venture rounds for Elevation, Pharvaris as Kodiak follow-on brings in $560M; plus AbCellera takes out Trianni for $90M and more
Elevation raises $65M series B, names Leland CEOElevation Oncology Inc. raised $65 million in a series B round and promoted founder Shawn Leland from CBO to CEO. The venture round was led by
BioCentury | Apr 22, 2020
Finance
April 21 Financial Quick Takes: ORIC’s IPO plans; plus venture rounds for Magpie, Cloudbreak, ReAlta, New Horizon, Zikani
BioCentury | May 28, 2019
Financial News
May 28 Financial Quick Takes: Alphamab Oncology raises $60M; plus $180.5M for Panacea healthcare fund and more
Items per page:
1 - 7 of 7